Effects of trastuzumab and lapatinib on HER2 positive breast cancer treatment.
This study aimed to evaluate the clinical efficacy of trastuzumab combined with lapatinib in the treatment of human epidermal growth factor receptor 2 (HER2) positive breast cancer. One hundred and fifty-four patients with breast cancer were randomly divided into a trastuzumab group (group A, 52 cases), a lapatinib group (group B, 48 cases) and a combination group (group C, 54 cases).